TrialStudy to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
Trial details
- Registry ID
- NCT04412668
- Phase
- Phase 2
ATYR
aTyr Pharma, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
3Trials in this database
3Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19NCT04412668 | ATYR | Phase 2 | Completed | 2020-10-23Actual |
| Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary SarcoidosisNCT05415137 | ATYR | Phase 3 | Completed | 2025-06-25Actual |
| Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)NCT05892614 | ATYR | Phase 2 | Recruiting | 2026-04Estimated |
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
Trial details
- Registry ID
- NCT05415137
- Phase
- Phase 3
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
Trial details
- Registry ID
- NCT05892614
- Phase
- Phase 2
Latest recorded trial changes
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
NCT05415137 · aTyr Pharma, Inc.
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
31 Jul 2025
+ After
25 Jun 2025
Recruitment status changed
− Before
Active not recruiting
+ After
Completed